Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance…
Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million
Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth
PITTSBURGH, Jan. 11, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. … [8731 chars]
Source: GlobeNewswire | Published: 2026-01-11T18:00:00Z
Credit: GlobeNewswire
